Last reviewed 2026-05-15 · How we verify

[14C]TAK-994 Intravenous Infusion

Takeda · Phase 1 active Small molecule

[14C]TAK-994 Intravenous Infusion is a Small molecule drug developed by Takeda. It is currently in Phase 1 development.

At a glance

Generic name	[14C]TAK-994 Intravenous Infusion
Sponsor	Takeda
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]TAK-994 Intravenous Infusion CI brief — competitive landscape report
[14C]TAK-994 Intravenous Infusion updates RSS · CI watch RSS
Takeda portfolio CI

Frequently asked questions about [14C]TAK-994 Intravenous Infusion

What is [14C]TAK-994 Intravenous Infusion?

[14C]TAK-994 Intravenous Infusion is a Small molecule drug developed by Takeda.

Who makes [14C]TAK-994 Intravenous Infusion?

[14C]TAK-994 Intravenous Infusion is developed by Takeda (see full Takeda pipeline at /company/takeda).

What development phase is [14C]TAK-994 Intravenous Infusion in?

[14C]TAK-994 Intravenous Infusion is in Phase 1.

Manufacturer: Takeda — full pipeline
Compare: [14C]TAK-994 Intravenous Infusion vs similar drugs
Pricing: [14C]TAK-994 Intravenous Infusion cost, discount & access